Sinequan

Quick links to important sections

Sinequan

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sinequan

Property Description
Active ingredient Doxepin Hydrochloride
Forms Capsules, Oral Concentrate, Topical Cream
Pharmacological class Tricyclic Antidepressant (TCA)
Origin Synthetic Compound

What Type of Medicine is Sinequan (Doxepin)?

Sinequan is a brand name for a prescription medication containing the synthetic active ingredient Doxepin Hydrochloride. It belongs to the foundational pharmacological category of Tricyclic Antidepressants (TCAs), making it a well-established psychotropic agent designed to influence the nervous system. This classification relates to the drug's role in modulating neurochemical balance within the central nervous system. Doxepin is characterized as a non-selective monoamine reuptake inhibitor, distinguishing it from other antidepressant classes because its mechanism involves regulating multiple key neurochemicals, including both norepinephrine and serotonin.


Composition and Available Forms of Doxepin

The medication is a single-active-ingredient product, with all clinical effects stemming exclusively from the molecule Doxepin Hydrochloride. For systemic effects, Doxepin is available in forms designed for oral administration, specifically as capsules and an oral concentrate. The availability of both forms allows for flexible titration, which can be useful in managing conditions like sleep disturbances. The versatility of the compound is further demonstrated by the availability of topical formulations (creams), which are intended for localized, rather than systemic, application. In its systemic form, the medication is used to help improve mood and sleep.


General Therapeutic Purpose and Action Profile

The general therapeutic purpose of Doxepin is derived from its dual mechanism: modulating neurotransmitters and potently blocking histamine receptors. Its primary systemic function involves helping to stabilize depressed mood and alleviate associated tension. The strong action as a histamine H1 antagonist provides a distinct, dose-dependent effect, making it effective for facilitating sleep and providing relief from severe generalized itching (pruritus). This dual action profile, particularly the potent H1 antagonism, is a key factor that makes Doxepin applicable across psychiatric and dermatological contexts.

Regulatory References

  1. NIH MedlinePlus Doxepin (Depression, Anxiety) Information

What side effects are possible with Sinequan?

Possible Side Effects and Safety Information

The safety profile of Doxepin (Sinequan) is formally classified by regulatory documents, defining potential effects by frequency and the body system affected. These classifications highlight the drug's properties, particularly its effects on the nervous and gastrointestinal systems.


Common and System-Organ Effects

Side effects frequently reported in official labeling are often related to the drug's action on the central nervous system and its anticholinergic properties. The most Common adverse reactions include drowsiness/somnolence, dry mouth, and constipation [Reference ID: 5619040 - FDA], typically classified under Nervous System and Gastrointestinal Disorders. Other documented effects include dizziness, tremor, and blurred vision.


Serious Safety Concerns and Restrictions

Official regulatory documents emphasize specific serious risks. The medication is associated with an increased risk of Suicidal Ideation and Behavior, particularly in young adults during the initial months of treatment or following dose changes [DOXEPIN HYDROCHLORIDE CAPSULES - FDA].

Furthermore, Doxepin carries a risk for the activation of mania or hypomania and may precipitate an acute attack of Angle-Closure Glaucoma in susceptible individuals. Due to the potential for exacerbation, the medicine is contraindicated in patients with a tendency to urinary retention or pre-existing severe liver disease [Doxepin 25 mg Capsules - SmPC].

Population-Specific Safety Notes are required for certain groups. Older adults may be more susceptible to toxic effects like agitation and confusion. Use is contraindicated during lactation due to documented risks of effects like apnea and drowsiness in the nursing infant [SINEQUAN® CAPSULES ORAL CONCENTRATE - FDA].

Overdose and Emergency Response

A suspected overdose of Sinequan (Doxepin) must be treated as a medical emergency requiring immediate professional attention, as indicated by official regulatory guidance. The regulatory labeling states that the most serious manifestations involve the cardiovascular and central nervous systems, which may be life-threatening.

Documented Signs and Severe Outcomes

Overdose may present with critical signs such as cardiac dysrhythmias and severe hypotension. Central Nervous System effects range from profound CNS depression leading to coma and loss of consciousness, to signs of excitation including convulsions (seizures), agitation, and lack of coordination. Clinical severity is often indicated by changes on the EKG, specifically a maximal limb-lead QRS duration of ge 0.1 seconds. Other documented manifestations include severe anticholinergic symptoms like urinary retention, blurred vision, and severe confusion. Increased susceptibility to unwanted effects is noted for the elderly population.

Required Emergency Actions

Due to the documented risk of life-threatening cardiac and neurological complications, official regulatory guidance mandates that individuals seek immediate medical attention for any suspected overdose. Emergency management is strictly supportive and symptomatic. Procedures officially described include administering intravenous Sodium Bicarbonate to manage cardiovascular toxicity and using Benzodiazepines to control seizures. The official labeling notes that agents such as physostigmine are generally to be avoided.

Therapeutic Uses of Sinequan

Sinequan (Doxepin) is generally applied across three primary therapeutic domains, offering support for patients dealing with symptomatic discomfort. It is commonly used when supportive symptom management is appropriate to help achieve or maintain daily stability.

This medication is relevant in clinical settings marked by symptoms related to heightened emotional and cognitive tension, including Major Depressive Disorder (MDD) and various anxiety neuroses. It is applied in addressing symptom clusters that may become intense or disruptive, such as persistent depressed mood, chronic tension, and worry.

“This medication is applied in addressing symptom clusters that may become intense or disruptive.”

Sinequan is also considered relevant in clinical settings marked by disturbed sleep continuity, primarily when a patient experiences difficulty remaining asleep through the night. It is commonly used for the short-term management of severe generalized itching (pruritus) associated with chronic skin conditions like atopic dermatitis. It helps ease the overall symptom load, providing supportive relief when symptoms interfere with routine activities.

Quick Fact: Supportive Management for Severe Pruritus and Sleep Maintenance

Regulatory References

  1. DailyMed: Doxepin Hydrochloride Capsule Label

Eligibility and Restrictions for Use

Who Can and Cannot Use Sinequan (Doxepin)?

Eligibility for Sinequan (Doxepin Hydrochloride) is determined strictly by regulatory guidelines based on a patient's pre-existing conditions, age, and concurrent therapies.

Absolute Contraindications

Sinequan must not be used by individuals with a known hypersensitivity to doxepin or other dibenzoxepines. Use is also prohibited in patients diagnosed with glaucoma or those with a tendency toward urinary retention (due to the drug's anticholinergic effects). Additionally, it is contraindicated if the patient is taking or has stopped a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days.

Age and Special Population Restrictions

Population Eligibility Status Regulatory Requirement
Adults (18+) Generally Approved Close supervision required for elderly patients (65+) who are more susceptible to toxic effects.
Pediatric Patients Not Approved Safety and effectiveness have not been established; use is not recommended in children under 12 years of age.

Conditional Use and Restrictions

Patients with hepatic impairment may require a dose adjustment due to potentially altered drug concentrations. Furthermore, patients should be screened for a history of bipolar disorder before starting treatment, as the drug is not approved for bipolar depression and may activate mania. Breastfeeding is not recommended because the drug is excreted into human milk.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile of Sinequan (Doxepin) is structured by official regulatory information concerning mandatory prohibitions, metabolic pathways, and pharmacodynamic effects.


Official Regulatory Interaction Constraints

Constraint Type Interacting Agent or Condition Official Requirement or Classification
Formal Contraindication Monoamine Oxidase Inhibitors (MAOIs) Prohibited combination; use is also contraindicated in untreated narrow-angle glaucoma and severe urinary retention.
Timing Separation Monoamine Oxidase Inhibitors (MAOIs) A minimum of two weeks must pass after discontinuing an MAOI before Doxepin is initiated.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Metabolic Pathway Interference: Doxepin is metabolized primarily by the CYP2C19 and CYP2D6 enzyme systems. The official labeling confirms that co-administration with inhibitors of these enzymes may increase Doxepin plasma concentrations. Specifically, Cimetidine is documented to significantly increase Doxepin exposure by reducing its clearance.

Pharmacodynamic Augmentation: The sedative effects of Doxepin are officially noted to be potentiated when co-administered with substances that depress the central nervous system (CNS), including alcohol (ethanol), CNS depressants, and sedating antihistamines. Furthermore, a case of severe hypoglycemia has been reported with co-administration of Tolazamide.

Mechanism of Action

The action of Doxepin is characterized by a pleiotropic mechanism, meaning it engages multiple receptor and transporter systems simultaneously to produce its overall physiological effects.


Dual Modulation of Norepinephrine and Serotonin Transporters

Doxepin functions as a non-selective reuptake inhibitor, binding to the Norepinephrine Transporter (NET) and the Serotonin Transporter (SERT). By blocking the reabsorption of these neurotransmitters back into the presynaptic neuron, Doxepin increases their functional concentration in the synapse. This modulation leads to a gradual, time-dependent adaptation of neural signaling, leading to changes in neuronal signaling efficiency across central pathways.


High-Affinity Histamine H1 Receptor Antagonism

A dominant and rapid component of Doxepin's mechanism is its high-affinity antagonistic activity at the Histamine H1 Receptor. This blockade suppresses histaminergic signaling in the Central Nervous System (CNS) and peripheral tissues. The resulting physiological effect is the significant suppression of central arousal and the attenuation of local histamine-mediated signaling, which results in the physiological consequence of reduced central vigilance.


Non-Selective Antagonism of Autonomic Receptors

Doxepin also acts as a non-selective antagonist on other targets, including Muscarinic Acetylcholine Receptors and alpha1-Adrenergic Receptors. This off-target blockade interferes with the normal function of the autonomic nervous system. This mechanistic domain contributes to predictable physiological adjustments, such as altered vascular tone and reduced glandular secretions, inherent to the drug's overall profile.

Dosage and Administration Information

The usage of Sinequan (Doxepin) is defined by instructions detailing its administration routes, dosing patterns, and preparation requirements. The medication is prescribed for use via two methods: oral administration (capsules, oral concentrate, or low-dose tablets) for systemic effect, and topical administration (5% cream) for localized use.

Dosing and Frequency Patterns

For systemic treatment of conditions like depression, the target total oral dosage range is 75 mg/day to 150 mg/day, beginning with a starting dose of 75 mg once daily or in divided doses. The maximum recommended dose is 300 mg per day. Doses up to 150 mg/day may be given as a single daily dose at bedtime to align with standard frequency patterns.

Preparation and Procedural Rules

The oral concentrate formulation requires mandatory dilution prior to administration; the measured dose must be immediately mixed with 120 mL of specific liquids, such as water, milk, or designated fruit juices. Furthermore, the low-dose tablets for sleep maintenance have a specific food timing restriction, mandating they not be taken within 3 hours of consuming a meal.

Administration Constraints

Specialized instructions apply to certain populations and procedural steps. Older adults typically begin treatment at a lower initial dose, such as 10 mg daily, and are monitored closely. Topical application is restricted in area and duration, generally covering less than 10% of the body surface area (BSA). All systemic forms require the dosage to be gradually reduced (tapered) when treatment is stopped.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sinequan

Evidence for Use in Major Depressive Disorder and Anxiety Neuroses

This section will summarize the structure of the foundational evidence, including the older historical Randomized Controlled Trials (RCTs) and regulatory reviews that was studied for conditions related to depressed mood and anxiety. Researchers evaluated short-term symptom changes for depressed mood and anxiety neuroses in studies conducted during the initial development phase of the drug, focusing on adult patients. The findings describe patterns observed in the studies related to depression and anxiety rating scale scores across the observed populations.

Long-term outcomes related to systemic or functional imbalance are not well characterized. The evidence relies heavily on older trial methodology, and data for certain groups remain insufficient, particularly for pediatric populations, where the drug was not systematically studied.


Evidence for Use in Sleep Maintenance Difficulty (Insomnia)

This section will outline the structure of the more recent, high-quality Randomized, Double-Blind, Placebo-Controlled Trials specific to the low-dose formulation. These studies focused on both adults and older adults who were defined as having difficulty remaining asleep. The studies monitored objective sleep maintenance by measuring parameters such as Total Sleep Time (TST) and Wake Time After Sleep Onset (WASO) using specialized equipment. Research examined patterns related to objective sleep maintenance metrics across the intermediate follow-up duration (up to three months).

There is limited information for long-term outcomes for continuous use beyond the three-month follow-up durations assessed in the pivotal trials. The character of reported differences in objective sleep parameters was sometimes described as modest in some studies, and research does not determine whether an individual will respond similarly.


Evidence for Use in Severe Generalized Itching (Pruritus)

This section will review the evidence from the specific, short-term Randomized Controlled Trials (RCTs) conducted using the topical cream formulation. The research examined the use of the topical cream in adult patients with conditions such as severe generalized itching (pruritus) linked to chronic skin conditions. Studies reported measurements of difference in itching intensity compared to the control vehicle, with findings providing insight into the onset of patterns related to perceived discomfort.

This evidence is limited to the topical formulation and the short-term follow-up durations. Data for certain groups remain insufficient.

Key Studies & References

  1. Doxepin Hydrochloride Capsule Label: DailyMed

Frequently Asked Questions (FAQ)

Common questions about Sinequan (FAQ)


Q: What is the main difference between Sinequan and other antidepressants?

Sinequan is an older type of antidepressant, classified as a tricyclic antidepressant (TCA). Official information states its mechanism is non-selective, affecting both norepinephrine and serotonin. A key difference is its strong action on the Histamine H1 receptor, which contributes to its prominent and often desired sedative effects.


Q: How quickly does Sinequan start to affect sleep or anxiety?

Studies and official information indicate that the rapid action on the histamine receptor is responsible for the immediate sedative and sleep-inducing effects. The drug's official information suggests that effects on anxiety may be noticed before the full antidepressant effect, which is typically delayed.


Q: What are the most common reasons doctors prescribe Sinequan?

The systemic form of Doxepin (Sinequan) is officially indicated for psychoneurotic patients who experience depression and/or anxiety. Additionally, a low-dose tablet form of the active ingredient is indicated for use in treating insomnia characterized by difficulty staying asleep.


Q: Does Sinequan cause noticeable weight gain?

Official adverse event information states that changes in weight, including weight gain, have been reported in some patients taking Doxepin. Patients should be aware that this is a possibility, as it is occasionally observed.


Q: What foods or drinks should you avoid while taking Sinequan?

Regulatory warnings caution against the use of alcohol while taking this medication, as it can significantly increase the central nervous system depressant effects of Sinequan. Furthermore, the low-dose tablet form used for sleep maintenance has a specific requirement that it should not be taken within three hours of consuming any meal.


Q: Can taking Sinequan affect your ability to drive or operate machinery?

Yes, the official label cautions that the medication can impair the mental and physical abilities needed to perform hazardous tasks, such as driving or operating machinery. This is due to its sedative properties, which can affect alertness and motor coordination.


Q: What happens if you miss a dose of Sinequan?

Official product labeling provides specific guidance for managing missed doses. Generally, patients are advised not to double their dose to compensate for a missed one. Patients should follow the exact instructions provided by their prescriber or pharmacist regarding missed doses.


Q: How long does Sinequan stay in your system after you stop taking it?

According to pharmacokinetic data, the active ingredient doxepin has an approximate terminal half-life of 15.3 hours. Its primary active metabolite, nordoxepin, has a longer half-life of approximately 31 hours, meaning the medication and its effects can persist in the body for an extended period after the last dose.


Q: Can Sinequan cause dry mouth, and if so, how is that managed?

Dry mouth is a commonly reported side effect related to the drug's anticholinergic properties. If this or other related effects, such as blurred vision or constipation, become severe, official guidelines note that dose reduction may be considered as a clinical option.


Q: What research studies support the use of Sinequan for anxiety?

The official indication for anxiety neuroses is based on controlled clinical trials that were conducted during the initial development phase of the drug. These studies established its effectiveness for treating anxiety associated with psychoneurotic conditions.


Q: Are there generic versions of Sinequan available?

While the brand name Sinequan has been discontinued in the United States, its active ingredient, Doxepin, is widely available in generic form. These generic products contain the same active ingredient, Doxepin Hydrochloride.


Q: Why is Sinequan sometimes prescribed for insomnia?

Sinequan contains the active ingredient Doxepin, which has a powerful and highly specific action as an antagonist (blocker) at the Histamine H1 receptor. This mechanism suppresses central arousal in the brain and is the direct reason why the low-dose formulation is indicated for sleep maintenance difficulty.


Q: What are the signs that Sinequan is starting to work for depression?

The full antidepressant effect is typically delayed. Studies indicate that symptom relief may be observed after 10 days or more of consistent treatment. Symptoms that have shown response in studies include depressed mood, anxiety, tension, and excessive physical concern.


Q: Is it normal to feel dizzy or lightheaded when standing up on Sinequan?

The medication can cause dizziness, faintness, or lightheadedness when changing position. The official label notes that this can occur when getting up from sitting or lying down.


Q: Can men or women experience sexual side effects from Sinequan?

Yes, regulatory documents mention that both men and women may experience sexual adverse effects while taking Doxepin. These may include a decreased interest in or loss of sexual ability, desire, drive, or performance.


Q: How often do people need follow-up appointments when taking Sinequan?

Regulatory warnings highlight the importance of close monitoring, especially for young adults, during the initial months of treatment or following dose adjustments. This monitoring is intended to watch for clinical worsening or the emergence of suicidal thoughts and behaviors.


Q: Can Sinequan be taken with acid reflux medication?

The official labeling documents a significant drug-drug interaction with Cimetidine, a medication formerly common for acid reduction, stating that Cimetidine can increase the concentration of Doxepin in the blood. It is important that all concurrent medications be disclosed to a healthcare professional.


Q: Does Sinequan show up on standard drug tests?

While Doxepin itself is generally not part of routine drug screens, it has been reported that its use can potentially cause a false-positive result for amphetamines on certain tests. If a patient is undergoing drug screening, they may need to inform testing personnel of their medication use.


Q: Does Sinequan interact with allergy medications or antihistamines?

Sinequan should be used with caution alongside other medications that affect the central nervous system. The official prescribing information notes that its sedative effects are potentiated (increased) when co-administered with other sedating antihistamines or CNS depressants.


Q: Are there any physical or lab tests required before starting Sinequan?

Regulatory guidance requires patients to be screened for any personal or family history of bipolar disorder, mania, or hypomania before starting treatment. Additionally, patients with hepatic impairment (liver problems) may require dose adjustments and subsequent monitoring.


Q: Does Sinequan cause changes in appetite?

Yes, official safety information lists changes in appetite as a possible side effect of the medication. This can manifest alongside the possibility of weight changes.


Q: Does Sinequan affect memory or concentration?

Sinequan is categorized as a central nervous system (CNS) depressant, and its effects can potentially impair mental functions. Reported side effects include confusion and disturbed concentration.


How should Sinequan be stored and disposed of?

How to Store and Dispose of Sinequan

Official regulatory documents define strict requirements for storing and disposing of Sinequan (doxepin) capsules to maintain stability and ensure safety.

Storage Conditions

Sinequan must be kept at Controlled Room Temperature, which is between 68 F and 77 F (20 C and 25 C). The medication should be stored in the container it came in, with the lid tightly closed, and must be protected from both excessive heat and excessive moisture.

Furthermore, the capsules must be protected from light and kept in a secure location. It is mandated to keep this medication out of the reach of children.

Disposal Protocol

Unused or expired Sinequan should be disposed of through a medicine take-back program whenever possible. If a take-back program is not available, the medication must be mixed with an unappealing substance, such as used coffee grounds or cat litter, and placed in a sealed bag before being thrown into the household trash. The official protocol states that Sinequan must not be flushed down a toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sinequan found in:

A-Z Index: